Weill Cornell Medicine and Weill Bugando School of Medicine collaborate to strengthen medical education, health care and innovative global health research at both institutions.
Working toward more effective tuberculosis vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with “kill switches” that can be triggered to stop the bacteria after they activate an immune response.
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine investigators.
An interdisciplinary team of Cornell researchers is developing HelioSkin, an aesthetically appealing solar-collection fabric that is inspired by the biological mechanisms that enable plants to bend toward the sun.
A multinational, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
Weill Cornell Medicine researchers have found that intracranial hemorrhages, or “brain bleeds” caused by a ruptured blood vessel in the brain, doubles a person’s risk of developing dementia later in life.
Weill Cornell Medicine physician-scientists Dr. Niroshana Anandasabapathy and Dr. Rohit Chandwani have been elected members of the American Society for Clinical Investigation for 2025.
Blood clots form in response to signals from the lungs of cancer patients – not from other organ sites, as previously thought – according to a preclinical study by Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and University of California San Diego Health.
The resulting atlas advances basic research on the biology of the pancreas and could lead to new treatment strategies for diabetes and other pancreatic diseases.
